The
Biopharmaceutical CMO and CRO Market mainly involves contract manufacturing
organizations (CMOs) and contract research organizations (CROs) that provide
third-party services to biologics manufacturers and pharmaceutical companies
involved in the development and manufacturing of biologic drugs, including
vaccines, monoclonal antibodies and other therapeutic proteins. CMOs offer
manufacturing services such as drug development, clinical and bulk production,
fill-finish works and labeling. CROs support drug development through carrying
out research studies, clinical trials and regulatory consulting. The growing
trend of outsourcing manufacturing and R&D activities to CMOs and CROs has
significantly reduced costs and accelerated time to market for pharmaceutical
companies.
The Global Biopharmaceutical CMO and CRO Market is
estimated to be valued at US$ 41.71 Mn in 2024 and is expected to exhibit a
CAGR of 5.0% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Biopharmaceutical CMO and CRO Market are
Albemarle Corporation, Greenchemicals S.r.l., ICL, Jordan Bromine Company,
Kingboard Holdings Limited, LANXESS, Novel Chem, Shandong Brother Sci. &
Tech. Co., Ltd., Shandong Futong Chemical Co., Ltd. and Tianjin Changlu Hangu Saltern
Co., Ltd. These players provide comprehensive manufacturing and research
services to establish partnerships with pharmaceutical companies.
The growing demand for
Biopharmaceutical
CMO and CRO Market Demand such as monoclonal antibodies and recombinant
proteins is driving significant outsourcing of manufacturing activities to
CMOs. CMOs are well-equipped to handle complex large-scale production of
biologics. Outsourcing to CMOs helps reduce costs and ensures reliability of
supply.
CMOs and CROs are also expanding globally with new facilities to meet the
rising demand from multinational pharmaceutical companies. Many players are
setting up manufacturing plants and R&D centers in emerging markets to
capitalize on low-cost talent and lucrative business opportunities. This global
expansion allows better servicing of local as well as international clientele.
Market Key Trends
One of the major trends in the Biopharmaceutical CMO and CRO Market is the
increasing adoption of single-use bioprocessing technologies. Using single-use
systems allows flexible utilization of facility and eliminates downtime related
to cleaning of fixed stainless steel equipment. This improves productivity and
speeds up development timelines. Single-use bioprocessing also removes the need
for capital-intensive stainless steel infrastructure, making outsourcing more
affordable. It is expected that single-use systems will become mainstream
across CMOs and CROs in the coming years.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical CMO and
CRO market requires huge capital investments for R&D infrastructure which
poses significant barrier for new players.
Bargaining power of buyers: Individual buyers in this market have relatively
low bargaining power due to the specialized nature of services provided by CMOs
and CROs.
Bargaining power of suppliers: Due to limited suppliers of raw materials and
expertise required for biologics development, suppliers enjoy moderate
bargaining power in this market.
Threat of new substitutes: There exists low threat of substitutes given
biologics require specialized manufacturing facilities and expertise making it
difficult to substitute.
Competitive rivalry: The market is highly competitive with presence of global
and regional players. However, market attracts new investments to build
capabilities for biologics manufacturing.
Geographical regions: North America currently dominates the market and accounts
for over 35% of the global value owing to presence of majority of top biopharma
companies and CMOs & CROs in the US.
Asia Pacific region is expected to grow at the fastest pace during the forecast
period driven by increasing outsourcing of bioproduction as well as growing
biotech industry and investments in emerging countries like China and India.
Countries are developing indigenous manufacturing capabilities to fulfil rising
healthcare demands.
Get more insights on Biopharmaceutical
CMO And CRO Market
Priya Pandey is a dynamic and passionate editor with over
three years of expertise in content editing and proofreading. Holding a bachelor's
degree in biotechnology, Priya has a knack for making the content engaging. Her
diverse portfolio includes editing documents across different industries,
including food and beverages, information and technology, healthcare, chemical
and materials, etc. Priya's meticulous attention to detail and commitment to
excellence make her an invaluable asset in the world of content creation and
refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
Comments
Post a Comment